Evidence map›Paper›PMID 38302313›Full record

ReviewSeminars in hematology2024

Vaccinations in patients with chronic lymphocytic leukemia.

Elizabeth R Francis, Jennifer Vu, Catherine Ostos Perez, Clare Sun

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Elizabeth R FrancisNational Institutes of Health, National Cancer Institute.
Jennifer VuRosalind Franklin University of Medicine and Science, Chicago Medical School.
Catherine Ostos PerezNational Institutes of Health, National Cancer Institute.
Clare SunNational Institutes of Health, National Heart, Lung, and Blood Institute. Electronic address: clare.sun@nih.gov.
National Institutes of Health · USRosalind Franklin University of Medicine and Science · US

Funding

Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by immune dysfunction resulting in heightened susceptibility to infections and elevated rates of morbidity and mortality. A key strategy to mitigate infection-related complications has been immunization against common pathogens. However, the immunocompromised status of CLL patients poses challenges in eliciting an adequate humoral and cellular immune response to vaccination. Most CLL-directed therapy disproportionately impairs humoral immunity. Vaccine responsiveness also depends on the phase and type of immune response triggered by immunization. In this review, we discuss the immune dysfunction, vaccine responsiveness, and considerations for optimizing vaccine response in patients with CLL.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellVaccinationHumansImmunity, HumoralImmunocompromised HostChronic lymphocytic leukemiaCLLCOVID-19Hepatitis BHerpes zosterImmune dysfunctionInfluenzaPneumococcalTDaPVaccine

Identifiers

PMID38302313
PMCPMC11162341
OpenAlexW4390640273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.